Therapy News and Research

RSS

Inhibition of PBEF could be potential therapeutic target for pulmonary hypertension

Inhibition of pre-B Cell Colony-Enhancing Factor (PBEF) could be a potential therapeutic target for pulmonary hypertension (PH), according to a preclinical study in an animal model of PH.

23 May 2012

IACs may increase risk of arrhythmias in young individuals with asthma

Use of inhaled anticholinergics (IACs) has been associated with an increased risk of potentially dangerous heart arrhythmias among young asthma patients, according to a study conducted by researchers at the University of Illinois at Chicago.

23 May 2012

IntelliCell enters sponsored research agreement with ICERM

IntelliCell BioSciences, Inc. announced today that it has entered a sponsored research agreement with the Institute for Cell Engineering and Regenerative Medicine (ICERM) at the University of Florida.

23 May 2012

Children with craniofacial disorders face numerous medical challenges beyond appearance

Children born with cleft lip, cleft palate and other craniofacial disorders face numerous medical challenges beyond appearance.

23 May 2012

Combination therapy does not reduce mortality rates associated with severe sepsis

Frank M. Brunkhorst, M.D., of Friedrich-Schiller University, Jena, Germany, and colleagues conducted a study to compare the effect of the antibiotics moxifloxacin and meropenem with the effect of meropenem monotherapy on sepsis-related organ dysfunction.

22 May 2012

Medtronic fourth quarter revenue increases 4% to $4.297 billion

Medtronic, Inc. today announced financial results for its fourth quarter and fiscal year ended April 27, 2012.

From Medtronic 22 May 2012

Gattex may represent new treatment approach for short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported the presentation of data at the Digestive Disease Week (DDW) meeting held May 19-22 in San Diego.

22 May 2012

GE Healthcare, KUH partner to drive advances in cell therapy technologies

Karolinska University Hospital Sweden and GE Healthcare Life Sciences today announced a joint research collaboration to drive advances in technologies and workflows for use in the rapidly emerging field of cell therapy.

22 May 2012

Inexpensive sleep disorder drug appears to be potent inhibitor of cancer cells

An inexpensive "orphan drug" used to treat sleep disorders appears to be a potent inhibitor of cancer cells, according to a new study led by scientists at Fred Hutchinson Cancer Research Center.

22 May 2012

$Bisphosphonate therapy may increase risk of atypical femoral fractures$

Bisphosphonate therapy may increase risk of atypical femoral fractures

Treatment with bisphosphonate therapy appears to be associated with an increased risk of atypical fractures of the femur, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.

22 May 2012

Researchers to create new type of bioactive coating for brain aneurysm stents

Researchers at Purdue University are working with the U.S. Army and neurosurgeons at the Walter Reed National Military Medical Center to create a new type of "bioactive" coating for stents used to treat brain aneurysms including those caused by head trauma from bomb blasts.

22 May 2012

New research reveals effective treatments for gastrointestinal conditions

New research being presented at Digestive Disease Week- (DDW) reveals effective treatments for a number of gastrointestinal conditions, which are often chronic and costly.

22 May 2012

European study on allergies investigates birch, olive and grass pollens

From Finland to Italy and from Spain to Lithuania, thirteen research institutes from eleven European countries took part in the three-year Hialine study. The coordinator was Professor Dr Jeroen Buters of TUM's Chair of Molecular Allergology and the Center of Allergy & Environment.

22 May 2012

FSU announces availability of Pacifier Activated Lullaby device

Many premature babies enter the world with a mountain of challenges in front of them. Even after they overcome any life-threatening issues, they face ongoing, and typically unpleasant, medical procedures, long hospital stays and increased chances of chronic health issues throughout their lives.

22 May 2012

TransCytos, Enginasion collaborate to develop new transfection technology

Enginasion and TransCytos announced today that their collaboration has resulted in a prototype 'transfection' technology that is designed to have a dramatic and positive impact on the drug-research industry.

22 May 2012

Intermountain signs collaborative research agreement with Myriad

Intermountain Healthcare and Myriad Genetics today announced they have signed a collaborative research agreement. The purpose of this agreement is to perform research and validation studies on transformative molecular diagnostic tests being developed by Myriad in an effort to improve the care and treatments for patients at Intermountain and around the world.

22 May 2012

Combination of vitamin D and BCG vaccine improves bladder cancer survival

The tuberculosis vaccine is often used as a treatment for bladder cancer, and adding vitamin D might improve the vaccine's effectiveness, according to new research from the University of Rochester Medical Center presented today at the American Urological Association annual meeting.

22 May 2012

HSF-1 protein likely source of chemotherapy-related heart damage in mice

Blocking a protein in the heart that is produced under stressful conditions could be a strategy to prevent cardiac damage that results from chemotherapy, a new study suggests.

22 May 2012

MGH develops new technique to reconstruct the larynx after surgery for advanced cancer

Massachusetts General Hospital (MGH) surgeons have developed a new technique for reconstructing the larynx after surgery for advanced cancer.

22 May 2012

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents.

22 May 2012